Merus NV
2GH
Company Profile
Business description
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Contact
Uppsalalaan 17
Utrecht3584 CT
NLDT: +31 302538800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
260
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,918.70 | 27.80 | 0.31% |
| CAC 40 | 8,113.56 | 14.09 | 0.17% |
| DAX 40 | 23,771.46 | 3.50 | 0.01% |
| Dow JONES (US) | 47,427.12 | 314.67 | 0.67% |
| FTSE 100 | 9,711.57 | 17.64 | 0.18% |
| HKSE | 25,858.89 | 87.04 | -0.34% |
| NASDAQ | 23,214.69 | 189.10 | 0.82% |
| Nikkei 225 | 50,253.91 | 86.81 | 0.17% |
| NZX 50 Index | 13,489.15 | 56.95 | 0.42% |
| S&P 500 | 6,812.61 | 46.73 | 0.69% |
| S&P/ASX 200 | 8,614.10 | 22.30 | 0.26% |
| SSE Composite Index | 3,888.60 | 13.34 | 0.34% |